Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 3, 2015, Pages 1117-1122

  Prasaja, Yenny ^a   Sutandyo, Noorwati ^b   Andrajati, Retnosari ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b Dharmais Cancer Hospital National Cancer Center   (Indonesia)

Author keywords

Cisplatin; Dharmais Hospital; Hydration; Nephrotoxicity; Risk factor

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE;

ADULT; BLOOD; CANCER STAGING; CHEMICALLY INDUCED; COMORBIDITY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; COMORBIDITY; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84929321171     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.3.1117     Document Type: Article

References (44)

1. Aapro M, Launay-Vacher V (2012). Importance of monitoring renal function in patients with cancer. Cancer Treat Rev, 38, 235-40.
2. American Cancer Society (2008). Global cancer facts and figures 2008 2nd edition. [online]. [cited on March 28th, 2014] http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
3. Ardizzoni A, Boni L, Tiseo M, et al (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 99, 847-57.
4. Arunkumar PA, Viswanatha GL, Radheshyam N, et al (2012). Science behind cisplatin-induced nephrotoxicity in humans: a clinical study. Asian Pac J Trop Biomed, 2, 640-4.
5. BC Cancer Agency Cancer Drug Manual (2013). Cisplatin. [cited on June 3rd, 2013] http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Cisplatin.htm
6. Bell JS, Blacker N, LeBlanc VT, et al (2013). Prescribing for older people with chronic renal impairment. Aust Fam Physician, 42, 24-8.
7. Caglar K, Kinalp C, Arpaci F, et al (2002). Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant, 17, 1931-5.
8. Chu E, Sartorelli AC (2012). Cancer chemotherapy. In 'Basic and Clinical Pharmacology', Eds Katzung BG, Masters SB, Trevor AJ. 12nd ed. McGraw-Hill Companies Inc., USA pp 949-75.
9. Corwin EJ (2008). Hypertension. Diabetes mellitus. In 'Handbook of Pathophysiology'. 3rd ed. Lippincott Williams and Wilkins, USA pp 430-34, 556-70.
10. de Jongh FE, van Veen RN, Veltman SJ, et al (2003). Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer, 88, 1199-206.
11. Erten C, Demir L, Somali I, et al (2013). Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev, 14, 3711-7.
12. Fine LG, Norman JT (2008). Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int, 74, 867-72.
13. Food and Drug Administration [FDA] (2010). Guidance for industry: Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. [cited on Sept 10th, 2013] http://www.fda.gov/downloads/Drugs/./Guidances/UCM204959.pdf
14. Fujieda M, Matsunaga A, Hayashi A, et al (2009). Children's toxicology from bench to bed-drug-induced renal injury (2): nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci, 34, 251-7.
15. Ghazali MV, Sastromihardjo S, Soedjarwo SR, et al (2011). A cross-sectional study. In 'Fundamentals of Clinical Research Methodology, Eds Sastroasmoro S and Ismael S. 4th ed. CV. Sagung Seto, Jakarta pp 130-45 (in Indonesian).
16. Grover B, Buckley D, Buckley AR, et al (2004). Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther, 308, 949-56.
17. Hill GS (2008). Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens, 17, 266-70.
18. Hotta K, Matsuo K, Ueoka H, et al (2004). Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 22, 3852-9.
19. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
20. Khrunin A, Ivanova F, Moisseev A, et al (2012). Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics, 13, 171-8.
21. Kroning R, Lichtenstein AK, Nagami GT (2000). Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol, 45, 43-9.
22. Lacy CF, Armstrong LL, Goldman MP, et al (2011). Cisplatin. In 'Drug Information Handbook'. 20th ed. Lexi Comp., Ohio, 348-9.
23. Lavole A, Danel S, Baudrin L, et al (2012). Routine administration of a single dose of cisplatin ≥75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer, 99, 43-8.
24. Leu L, Baribeault D (2010). A comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract, 16, 167-71.
25. Mathe C, Bohacs A, Duffek L, et al (2011). Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J, 37, 888-94.
26. Miller RP, Tadagavadi RK, Ramesh G, et al (2010). Mechanisms of cisplatin nephrotoxicity. Toxins, 2, 2490-518.
27. Moon HH, Seo KW, Yoon KY, et al (2011). Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol, 17, 3510-7.
28. Morgan KP, Buie LW, Savage SW (2012). The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother, 46, 276-81.
29. Muraki K, Koyama R, Honma Y, et al (2012). Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advenced non-small cell lung cancer. J Thorac Dis, 4, 562-8.
30. Naughton CA (2008). Drug-induced nephrotoxicity. Am Fam Physician, 78, 743-50.
31. Pabla N, Dong Z (2008). Cisplatin nephrotoxicity: mechanism and renoprotective strategies. Kidney Int, 73, 994-1007.
32. Perazella MA (2009). Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol, 4, 1275-83.
33. Reed E (2008). Pharmacology of cancer chemotherapy: cisplatin and its analogues. In 'Cancer Principles and Practice of Oncology', Eds De Vita VT Jr, Hellman S, Rosenberg SA. 8th ed. Lippincott Willians and Wilkins, Philadelphia.
34. Ries F, Klastersky J (1986). Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis, 8, 368-79.
35. Santoso JT, Lucci JA 3rd, Coleman RL, et al (2003). Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol, 52, 13-8.
36. Sinuraya ES (2012). The hospital based-cancer registry at Dharmais cancer hospital 2003-2007. Jakarta: Indonesian J Cancer, 11-67 (in Indonesian).
37. Stevens LA, Li S, Wang C, et al (2010). Prevalence of CKD and comorbid illness in elderly patients in the united states: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis, 55, 23-33.
38. Tan XL, Moyer AM, Fridley BL, et al (2011). Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res, 17, 5801-11.
39. Tezcan S, Izzettin FV, Sancar M, et al (2013). Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacol Pharmacy, 4, 296-302.
40. Thomas C, Thomas L (2009). Renal failure-measuring the glomerular filtration rate. Dtsch Arztebl Int, 106, 849-54.
41. Tiseo M, Martelli O, Mancuso A, et al (2007). Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori, 93, 138-44.
42. Wang J, Liu F, Huang DX, et al (2012). Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients. Asian Pac J Cancer Prev, 13, 4505-10.
43. Yamada K, Yoshida T, Zaizen Y, et al (2011). Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey. Jpn J Clin Oncol, 41, 1308-11.
44. Yao X, Panichpisal K, Kurtzman N, et al (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci, 334, 115-24.